IFNAR1 Degradation: A New Mechanism for Tumor Immune Evasion?

Romina E Araya; Romina S Goldszmid

doi:10.1016/j.ccell.2017.01.012

IFNAR1 Degradation: A New Mechanism for Tumor Immune Evasion?

Cancer Cell. 2017 Feb 13;31(2):161-163. doi: 10.1016/j.ccell.2017.01.012.

Authors

Romina E Araya¹, Romina S Goldszmid²

Affiliations

¹ Inflammatory Cell Dynamics Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
² Inflammatory Cell Dynamics Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA. Electronic address: rgoldszmid@mail.nih.gov.

Abstract

Type I interferons have been shown to play a major role in anti-cancer immunity. In this issue of Cancer Cell, Katlinski et al. describe tumor-induced degradation of type I interferon receptor IFNAR1 chain as a new immune-evasion mechanism in colorectal cancers. Stabilizing IFNAR1 inhibits tumor growth and improves immunotherapy efficacy.

Published by Elsevier Inc.

Publication types

Comment

MeSH terms

Humans
Interferon Type I / metabolism*
Tumor Escape*

Substances

Interferon Type I

Grants and funding

ZIA BC011670/ImNIH/Intramural NIH HHS/United States